Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.

Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J; Fabry Registry.

Genet Med. 2013 Dec;15(12):958-65. doi: 10.1038/gim.2013.53. Epub 2013 May 23.

PMID:
23703683
2.

Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.

Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, Beitner-Johnson D, Cizmarik M, Cole JA, Kingma W, Warnock DG.

Mol Genet Metab. 2012 Mar;105(3):443-9. doi: 10.1016/j.ymgme.2011.12.006. Epub 2011 Dec 14.

PMID:
22227322
3.

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Maródi L, Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; Fabry Registry.

Nephrol Dial Transplant. 2012 Mar;27(3):1042-9. doi: 10.1093/ndt/gfr420. Epub 2011 Jul 29.

4.

Cardiovascular events in patients with fabry disease natural history data from the fabry registry.

Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abiose A.

J Am Coll Cardiol. 2011 Mar 1;57(9):1093-9. doi: 10.1016/j.jacc.2010.11.018.

5.

Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.

Watt T, Burlina AP, Cazzorla C, Schönfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O'Brien F, Feldt-Rasmussen U.

Genet Med. 2010 Nov;12(11):703-12. doi: 10.1097/GIM.0b013e3181f13a4a.

PMID:
20885332
6.

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Maródi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2220-8. doi: 10.2215/CJN.04340510. Epub 2010 Sep 2.

7.

Regulation of catecholamines by sustained and intermittent hypoxia in neuroendocrine cells and sympathetic neurons.

Hui AS, Striet JB, Gudelsky G, Soukhova GK, Gozal E, Beitner-Johnson D, Guo SZ, Sachleben LR Jr, Haycock JW, Gozal D, Czyzyk-Krzeska MF.

Hypertension. 2003 Dec;42(6):1130-6. Epub 2003 Nov 3.

PMID:
14597643
8.

Mitogen- and ultraviolet-B-induced signaling pathways in normal human melanocytes.

Tada A, Pereira E, Beitner-Johnson D, Kavanagh R, Abdel-Malek ZA.

J Invest Dermatol. 2002 Feb;118(2):316-22.

9.

Calcium-dependent activation of Pyk2 by hypoxia.

Beitner-Johnson D, Ferguson T, Rust RT, Kobayashi S, Millhorn DE.

Cell Signal. 2002 Feb;14(2):133-7.

PMID:
11781137
10.

Hypoxia-inducible factor 2alpha binds to cobalt in vitro.

Yuan Y, Beitner-Johnson D, Millhorn DE.

Biochem Biophys Res Commun. 2001 Nov 9;288(4):849-54.

PMID:
11688986
11.

Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.

Seta KA, Kim R, Kim HW, Millhorn DE, Beitner-Johnson D.

J Biol Chem. 2001 Nov 30;276(48):44405-12. Epub 2001 Sep 27.

12.

Identification of hypoxia-responsive genes in a dopaminergic cell line by subtractive cDNA libraries and microarray analysis.

Beitner-Johnson D, Seta K, Yuan Y, Kim H, Rust RT, Conrad PW, Kobayashi S, Millhorn DE.

Parkinsonism Relat Disord. 2001 Jul;7(3):273-281.

PMID:
11331199
13.

Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells.

Beitner-Johnson D, Rust RT, Hsieh TC, Millhorn DE.

Cell Signal. 2001 Jan;13(1):23-7.

PMID:
11257444
14.

The molecular basis of O2-sensing and hypoxia tolerance in pheochromocytoma cells.

Conrad PW, Conforti L, Kobayashi S, Beitner-Johnson D, Rust RT, Yuan Y, Kim HW, Kim RH, Seta K, Millhorn DE.

Comp Biochem Physiol B Biochem Mol Biol. 2001 Feb;128(2):187-204. Review.

PMID:
11207433
15.

Novel regulation of p38gamma by dopamine D2 receptors during hypoxia.

Conrad PW, Millhorn DE, Beitner-Johnson D.

Cell Signal. 2000 Jul;12(7):463-7.

PMID:
10989281
16.
17.

Regulation of CREB by moderate hypoxia in PC12 cells.

Beitner-Johnson D, Rust RT, Hsieh T, Millhorn DE.

Adv Exp Med Biol. 2000;475:143-52.

PMID:
10849656
18.

Gene regulation during hypoxia in excitable oxygen-sensing cells: depolarization-transcription coupling.

Millhorn DE, Beitner-Johnson D, Conforti L, Conrad PW, Kobayashi S, Yuan Y, Rust R.

Adv Exp Med Biol. 2000;475:131-42. No abstract available.

PMID:
10849655
19.

Role of the D2 dopamine receptor in molecular adaptation to chronic hypoxia in PC12 cells.

Kobayashi S, Conforti L, Zhu WH, Beitner-Johnson D, Millhorn DE.

Pflugers Arch. 1999 Nov;438(6):750-9.

20.

EPAS1 trans-activation during hypoxia requires p42/p44 MAPK.

Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE.

J Biol Chem. 1999 Nov 19;274(47):33709-13.

21.

Selective activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells.

Conrad PW, Rust RT, Han J, Millhorn DE, Beitner-Johnson D.

J Biol Chem. 1999 Aug 13;274(33):23570-6.

22.

Regulation of gene expression and secretory functions in oxygen-sensing pheochromocytoma cells.

Conforti L, Kobayashi S, Beitner-Johnson D, Conrad PW, Freeman T, Millhorn DE.

Respir Physiol. 1999 Apr 1;115(2):249-60.

PMID:
10385038
23.
24.
25.

Hypoxia regulates the cAMP- and Ca2+/calmodulin signaling systems in PC12 cells.

Beitner-Johnson D, Leibold J, Millhorn DE.

Biochem Biophys Res Commun. 1998 Jan 6;242(1):61-6.

PMID:
9439610
26.

Regulation of gene expression by hypoxia: a molecular approach.

Beitner-Johnson D, Shull GE, Dedman JR, Millhorn DE.

Respir Physiol. 1997 Nov;110(2-3):87-97. Review.

PMID:
9407603
27.

Sphingosine 1-phosphate stimulates tyrosine phosphorylation of Crk.

Blakesley VA, Beitner-Johnson D, Van Brocklyn JR, Rani S, Shen-Orr Z, Stannard BS, Spiegel S, LeRoith D.

J Biol Chem. 1997 Jun 27;272(26):16211-5.

28.

The proto-oncogene Crk-II enhances apoptosis by a Ras-dependent, Raf-1/MAP kinase-independent pathway.

Parrizas M, Blakesley VA, Beitner-Johnson D, Le Roith D.

Biochem Biophys Res Commun. 1997 May 29;234(3):616-20.

PMID:
9175762
29.

Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling.

Rani CS, Wang F, Fuior E, Berger A, Wu J, Sturgill TW, Beitner-Johnson D, LeRoith D, Varticovski L, Spiegel S.

J Biol Chem. 1997 Apr 18;272(16):10777-83.

30.

Regulation of gene expression for tyrosine hydroxylase in oxygen sensitive cells by hypoxia.

Millhorn DE, Raymond R, Conforti L, Zhu W, Beitner-Johnson D, Filisko T, Genter MB, Kobayashi S, Peng M.

Kidney Int. 1997 Feb;51(2):527-35.

31.

The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling.

Beitner-Johnson D, Blakesley VA, Shen-Orr Z, Jimenez M, Stannard B, Wang LM, Pierce J, LeRoith D.

J Biol Chem. 1996 Apr 19;271(16):9287-90.

32.

Regulation of ionic conductances and gene expression by hypoxia in an oxygen sensitive cell line.

Millhorn DE, Conforti L, Beitner-Johnson D, Zhu W, Raymond R, Filisko T, Kobayashi S, Peng M, Genter MB.

Adv Exp Med Biol. 1996;410:135-42. Review.

PMID:
9030290
33.

Biochemical adaptations in the mesolimbic dopamine system in response to heroin self-administration.

Self DW, McClenahan AW, Beitner-Johnson D, Terwilliger RZ, Nestler EJ.

Synapse. 1995 Dec;21(4):312-8.

PMID:
8869161
34.

Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system.

Berhow MT, Russell DS, Terwilliger RZ, Beitner-Johnson D, Self DW, Lindsay RM, Nestler EJ.

Neuroscience. 1995 Oct;68(4):969-79.

PMID:
8545003
35.
36.

Molecular and cellular aspects of the insulin-like growth factor I receptor.

LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr.

Endocr Rev. 1995 Apr;16(2):143-63. Review. No abstract available.

PMID:
7540132
37.

Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk.

Beitner-Johnson D, LeRoith D.

J Biol Chem. 1995 Mar 10;270(10):5187-90.

39.

Chronic morphine impairs axoplasmic transport in the rat mesolimbic dopamine system.

Beitner-Johnson D, Nestler EJ.

Neuroreport. 1993 Oct 25;5(1):57-60.

PMID:
7506589
40.

Chronic morphine decreases insulin-like growth factor-I levels in the ventral tegmental area of the rat brain.

Beitner-Johnson D, Nestler EJ.

Ann N Y Acad Sci. 1993 Aug 27;692:246-8. No abstract available.

PMID:
8215026
41.
42.

Common intracellular actions of chronic morphine and cocaine in dopaminergic brain reward regions.

Beitner-Johnson D, Guitart X, Nestler EJ.

Ann N Y Acad Sci. 1992 Jun 28;654:70-87. Review. No abstract available.

PMID:
1352957
45.
46.

A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function.

Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ.

Brain Res. 1991 May 10;548(1-2):100-10.

PMID:
1651140
48.

Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates.

Rasmussen K, Beitner-Johnson DB, Krystal JH, Aghajanian GK, Nestler EJ.

J Neurosci. 1990 Jul;10(7):2308-17.

Supplemental Content

Loading ...
Support Center